Sample results33 results in the last year.

RNA-Binding Proteins: A Role in Neurotoxicity?

A Ochar�n-Mercado, J Loaeza-Loaeza…�- Neurotoxicity Research, 2023
Despite sustained efforts to treat neurodegenerative diseases, little is known at the
molecular level to understand and generate novel therapeutic approaches for these
malignancies. Therefore, it is not surprising that neurogenerative diseases are�…

Spatially coordinated heterochromatinization of long synaptic genes in fragile X syndrome

T Malachowski, KR Chandradoss, R Boya, L Zhou…�- Cell, 2023
Short tandem repeat (STR) instability causes transcriptional silencing in several
repeat expansion disorders. In fragile X syndrome (FXS), mutation-length expansion
of a CGG STR represses FMR1 via local DNA methylation. Here, we find megabase�…

Recent development and applications of ambient mass spectrometry imaging in pharmaceutical research: An overview

BS Kumar�- Analytical Methods, 2023
The application of ambient mass spectrometry imaging “MSI” is expanding in the
areas of fundamental research on drug delivery and multiple phases of the process
of identifying and developing drugs. Precise monitoring of a drug's pharmacological�…

Proteomics insights into fragile X syndrome: Unraveling molecular mechanisms and therapeutic avenues

DA Abbasi, E Berry-Kravis, X Zhao, SM Cologna�- Neurobiology of Disease, 2024
Abstract Fragile X Syndrome (FXS) is a neurodevelopment disorder characterized by
cognitive impairment, behavioral challenges, and synaptic abnormalities, with a
genetic basis linked to a mutation in the FMR1 (Fragile X Messenger�…

Anandamide and 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism based on FMR1 deletion in rats

S Schiavi, A Manduca, E Carbone, V Buzzelli, A Rava…�- Neuropsychopharmacology, 2023
Autism spectrum disorder (ASD) has a multifactorial etiology. Major efforts are
underway to understand the neurobiological bases of ASD and to develop
efficacious treatment strategies. Recently, the use of cannabinoid compounds in�…

Directly reprogrammed fragile X syndrome dorsal forebrain precursor cells generate cortical neurons exhibiting impaired neuronal maturation

N Edwards, C Combrinck, A McCaughey-Chapman…�- Frontiers in Cellular�…, 2023
Introduction The neurodevelopmental disorder fragile X syndrome (FXS) is the most
common monogenic cause of intellectual disability associated with autism spectrum
disorder. Inaccessibility to developing human brain cells is a major barrier to�…

Early postnatal development of the MDGA2+/-mouse model of synaptic dysfunction

E Fertan, AA Wong, TS Garvock-de Montbrun…�- Behavioural Brain Research, 2023
Synaptic dysfunction underlies many neurodevelopmental disorders (NDDs). The
membrane-associated mucin domain-containing glycosylphosphatidylinositol anchor
proteins (MDGAs) regulate synaptic development by modulating neurexin–neuroligin�…

Hyperexcitability in the olfactory bulb and impaired fine odor discrimination in the Fmr1 KO mouse model of fragile X syndrome

P Kuruppath, L Xue, F Pouille, ST Jones, NE Schoppa�- Journal of Neuroscience, 2023
Fragile X syndrome (FXS) is the single most common monogenetic cause of autism
spectrum disorders (ASDs) in humans. FXS is caused by loss of expression of the
fragile X mental retardation protein (FMRP), an mRNA-binding protein encoded on�…

Mutations in FUS lead to synaptic dysregulation in ALS-iPSC derived neurons

C Shum, EC Hedges, J Allison, Y Lee, N Arias…�- Stem Cell Reports, 2024
Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disorder
characterized by progressive muscular weakness due to the selective loss of motor
neurons. Mutations in the gene Fused in Sarcoma (FUS) were identified as one�…

WNT signalling control by KDM5C during development affects cognition

V Karwacki-Neisius, A Jang, E Cukuroglu, A Tai, A Jiao…�- Nature, 2024
Although KDM5C is one of the most frequently mutated genes in X-linked intellectual
disability, the exact mechanisms that lead to cognitive impairment remain unknown.
Here we use human patient-derived induced pluripotent stem cells and Kdm5c�…